{"generic":"Antihemophilic Factor VIII\/Von Willebrand Factor (Human)","drugs":["Alphanate","Antihemophilic Factor VIII\/Von Willebrand Factor (Human)","Humate-P","Wilate"],"mono":{"0":{"id":"928859-s-0","title":"Generic Names","mono":"Antihemophilic Factor VIII\/Von Willebrand Factor (Human)"},"1":{"id":"928859-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928859-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Bleeding - Hemophilia A:<\/b> dosage calculation:  body weight (kg) X factor VIII activity increase desired (%) divided by 2% per international unit per kg = dose required (international units) <\/li><li><b>Bleeding - Hemophilia A:<\/b> Alphanate(R): minor hemorrhage, 15 international units\/kg twice daily to increase FVIII levels to 30% of normal until hemorrhage stops (1 to 2 days)<\/li><li><b>Bleeding - Hemophilia A:<\/b> Alphanate(R): moderate hemorrhage, 25 international units\/kg twice daily to increase FVIII levels to 50% of normal until hemorrhage stops (2 to 7 days)<\/li><li><b>Bleeding - Hemophilia A:<\/b> Alphanate(R): major hemorrhage, 40 to 50 international units\/kg twice daily to increase FVIII levels to 80% to 100% % for at least 3 to 5 days. Then 25 international units\/kg twice daily until healing achieved for up to 10 days<\/li><li><b>Bleeding - Hemophilia A:<\/b> Humate-P(R): minor hemorrhage, loading dose, 15 international units\/kg to increase FVIII levels to 30% of normal, one dose may be sufficient; if needed 7.5 international units\/kg once or twice daily for 1 to 2 days<\/li><li><b>Bleeding - Hemophilia A:<\/b> Humate-P(R): moderate hemorrhage, loading dose, 25 international units\/kg to increase FVIII levels to 50% of normal, followed by 15 international units\/kg every 8 to 12 hours for 1 to 2 days to maintain FVIII levels at 30% of normal, then 15 international units\/kg once or twice daily for a total of up to 7 days or until adequate wound healing<\/li><li><b>Bleeding - Hemophilia A:<\/b> Humate-P(R): life-threatening hemorrhage, loading dose, 40 to 50 international units\/kg followed by 20 to 25 international units\/kg every 8 hours to maintain FVIII levels at 80% to 100% of normal for 7 days, then 20 to 25 international units\/kg once or twice daily for another 7 days to maintain the FVIII level at 30% to 50% of normal<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Alphanate(R): preoperative dose, 60 international units VWF:RCo\/kg IV; subsequent doses, 40 to 60 international units VWF:RCo\/kg IV every 8 to 12 hours as needed until healing is complete, dosing may be reduced after the third postoperative dose if necessary<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Alphanate(R): minor surgery goal: administer IV dose necessary to maintain von Willebrand factor activity or 40 to 50% during postop days 1 to 3<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Alphanate(R): major surgery goal: administer IV dose necessary to maintain von Willebrand factor activity or 40 to 50% during postop days 3 to 7<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Humate-P(R): emergency surgery, loading dose 50 to 60 international units VWF:RCo\/kg<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Humate-P(R): loading dose calculation involves acquiring individual in vivo recovery (IVR) values and is based on target peak VWF:RCo and FVIII:C levels, when not available a standardized loading dose may be used, VWF:RCo IVR of 2 IU\/dL per IU\/kg of VWF:RCo product administered<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Humate-P(R): initial maintenance dose should be half the loading dose<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Humate-P(R): subsequent maintenance dose is based on trough VWF:RCo and FVIII:C levels administered generally every 8 to 12 hours<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R): 40 to 80 international units of von Willebrand Factor measured with the ristocetin cofactor assay (VWF:RCo) (17 to 33 international units Factor VIII)\/kg every IV 8 to 12 hours, repeat as needed; 1 international unit of factor VIII activity\/kg will increase the circulating VWF:RCo of approximately 5 international units\/dL<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R): (type 1 mild disease and VWF:RCo activity greater than 30%) major hemorrhage, loading dose 40 to 60 international units VWF:RCo\/kg IV; maintenance dose, 40 to 50 international units VWF:RCo\/kg every 8 to 12 hours for 3 days to keep the VWF:RCo trough level greater than 50%; continue 40 to 50 international units VWF:RCo\/kg daily for a total of up to 7 days of treatment<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R): (type 1 moderate or severe disease and VWF:RCo activity less than 30%), minor hemorrhage, 40 to 50 international units VWF:RCo\/kg IV for 1 or 2 doses<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R): (type 1 moderate or severe disease and VWF:RCo activity less than 30%) major hemorrhage, loading dose of 50 to 75 international units VWF:RCo\/kg; maintenance dose, 40 to 60 international units VWF:RCo\/kg IV every 8 to 12 hours for 3 days to keep the VWF:RCo trough level greater than 50%; continue 40 to 60 international units VWF:RCo\/kg daily for a total of up to 7 days of treatment<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R): (types 2 (all variants) and type 3 disease), minor hemorrhage, 40 to 50 international units VWF:RCo\/kg IV for 1 or 2 doses<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R):(types 2 (all variants) and type 3 disease) major hemorrhage, loading dose 60 to 80 international units VWF:RCo\/kg IV; maintenance dose, 40 to 60 international units VWF:RCo\/kg every 8 to 12 hours for 3 days to keep the VWF:RCo trough level greater than 50%; continue 40 to 60 international units VWF:RCo\/kg daily for a total of up to 7 days of treatment<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Wilate(R): minor hemorrhage, loading dose of 20 to 40 international units of von Willebrand Factor measured with the ristocetin cofactor assay (VWF:RCo)\/kg IV at a rate of 2 to 4 mL\/min; maintenance dosage, 20 to 30 international units VWF:RCo\/kg IV at a rate of 2 to 4 mL\/min every 12 to 24 hr for up to 3 days to keep the VWF:RCo and FVIII activity trough levels greater than 30%<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Wilate(R): major hemorrhage, loading dose of 40 to 60 international units VWF:RCo\/kg IV at a rate of 2 to 4 mL\/min; maintenance dosage, 20 to 40 international units VWF:RCo\/kg IV at a rate of 2 to 4 mL\/min every 12 to 24 hr for up to 5 to 7 days to keep the VWF:RCo and FVIII activity trough levels greater than 50%<\/li><\/ul>"},"1":{"id":"928859-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Bleeding - Hemophilia A:<\/b> dosage calculation:  body weight (kg) X factor VIII activity increase desired (%) divided by 2% per international unit per kg = dose required (international units) <\/li><li><b>Bleeding - Hemophilia A:<\/b> Alphanate(R): minor hemorrhage, 15 international units\/kg twice daily to increase FVIII levels to 30% of normal until hemorrhage stops (1 to 2 days)<\/li><li><b>Bleeding - Hemophilia A:<\/b> Alphanate(R): moderate hemorrhage, 25 international units\/kg twice daily to increase FVIII levels to 50% of normal until hemorrhage stops (2 to 7 days)<\/li><li><b>Bleeding - Hemophilia A:<\/b> Alphanate(R): major hemorrhage, 40 to 50 international units\/kg twice daily to increase FVIII levels to 80% to 100% % for at least 3 to 5 days. Then 25 international units\/kg twice daily until healing achieved for up to 10 days<\/li><li><b>Bleeding - Hemophilia A:<\/b> Humate-P(R): minor hemorrhage, loading dose, 15 international units\/kg to increase FVIII levels to 30% of normal, one dose may be sufficient; if needed 7.5 international units\/kg once or twice daily for 1 to 2 days<\/li><li><b>Bleeding - Hemophilia A:<\/b> Humate-P(R): moderate hemorrhage, loading dose, 25 international units\/kg to increase FVIII levels to 50% of normal, followed by 15 international units\/kg every 8 to 12 hours for 1 to 2 days to maintain FVIII levels at 30% of normal, then 15 international units\/kg once or twice daily for a total of up to 7 days or until adequate wound healing<\/li><li><b>Bleeding - Hemophilia A:<\/b> Humate-P(R): life-threatening hemorrhage, loading dose, 40 to 50 international units\/kg followed by 20 to 25 international units\/kg every 8 hours to maintain FVIII levels at 80% to 100% of normal for 7 days, then 20 to 25 international units\/kg once or twice daily for another 7 days to maintain the FVIII level at 30% to 50% of normal<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Humate-P(R): emergency surgery, loading dose 50 to 60 international units VWF:RCo\/kg<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Humate-P(R): loading dose calculation involves acquiring individual in vivo recovery (IVR) values and is based on target peak VWF:RCo and FVIII:C levels, when not available a standardized loading dose may be used, VWF:RCo IVR of 2 IU\/dL per IU\/kg of VWF:RCo product administered<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Humate-P(R): initial maintenance dose should be half the loading dose<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Humate-P(R): subsequent maintenance dose is based on trough VWF:RCo and FVIII:C levels administered generally every 8 to 12 hours<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Alphanate(R): initial dose, 75 international units VWF:RCo\/kg IV<\/li><li><b>Bleeding - Surgical procedure - von Willebrand disorder:<\/b> Alphanate(R): subsequent doses, 50 to 75 international units VWF:RCo\/kg IV every 8 to 12 hours as needed until healing is complete, dosing may be reduced after the third postoperative dose if necessary<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R): 40 to 80 international units VWF:RCo (17 to 33 international units Factor VIII)\/kg every IV 8 to 12 hours, repeat as needed; 1 international unit of factor VIII activity\/kg will increase the circulating VWF:RCo of approximately 5 international units\/dL<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R): (type 1 mild disease and VWF:RCo activity greater than 30%) major hemorrhage, loading dose 40 to 60 international units VWF:RCo\/kg IV; maintenance dose, 40 to 50 international units VWF:RCo\/kg every 8 to 12 hours for 3 days to keep the VWF:RCo trough level greater than 50%; continue 40 to 50 international units VWF:RCo\/kg daily for a total of up to 7 days of treatment<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R): (type 1 moderate or severe disease and VWF:RCo activity less than 30%), minor hemorrhage, 40 to 50 international units VWF:RCo\/kg IV for 1 or 2 doses<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R): (type 1 moderate or severe disease and VWF:RCo activity less than 30%) major hemorrhage, loading dose of 50 to 75 international units VWF:RCo\/kg; maintenance dose, 40 to 60 international units VWF:RCo\/kg IV every 8 to 12 hours for 3 days to keep the VWF:RCo trough level greater than 50%; continue 40 to 60 international units VWF:RCo\/kg daily for a total of up to 7 days of treatment<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R): (types 2 (all variants) and type 3 disease), minor hemorrhage, 40 to 50 international units VWF:RCo\/kg IV for 1 or 2 doses<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Humate-P(R):(types 2 (all variants) and type 3 disease) major hemorrhage, loading dose 60 to 80 international units VWF:RCo\/kg IV; maintenance dose, 40 to 60 international units VWF:RCo\/kg every 8 to 12 hours for 3 days to keep the VWF:RCo trough level greater than 50%; continue 40 to 60 international units VWF:RCo\/kg daily for a total of up to 7 days of treatment<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Wilate(R): minor hemorrhage, loading dose of 20 to 40 international units of von Willebrand Factor measured with the ristocetin cofactor assay (VWF:RCo)\/kg IV at a rate of 2 to 4 mL\/min; maintenance dosage, 20 to 30 international units VWF:RCo\/kg IV at a rate of 2 to 4 mL\/min every 12 to 24 hr for up to 3 days to keep the VWF:RCo and FVIII activity trough levels greater than 30%<\/li><li><b>Bleeding - von Willebrand disorder:<\/b> Wilate(R): major hemorrhage, loading dose of 40 to 60 international units VWF:RCo\/kg IV at a rate of 2 to 4 mL\/min; maintenance dosage, 20 to 40 international units VWF:RCo\/kg IV at a rate of 2 to 4 mL\/min every 12 to 24 hr for up to 5 to 7 days to keep the VWF:RCo and FVIII activity trough levels greater than 50%<\/li><\/ul>"},"3":{"id":"928859-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Bleeding - Hemophilia A<\/li><li>Bleeding - Surgical procedure - von Willebrand disorder<\/li><li>Bleeding - von Willebrand disorder<\/li><\/ul>"}}},"3":{"id":"928859-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928859-s-3-9","title":"Contraindications","mono":"<ul><li>history of anaphylactic or severe systemic response to plasma-derived products, any ingredient in the formulation, or components of the container (Wilate(R))<\/li><li>history of anaphylactic or severe systemic response to antihemophilic factor VIII or von Willebrand factor products (Humate-P(R))<\/li><li>hypersensitivity to antihemophilic factor VIII, von Willebrand factor, or to any product component (Humate-P(R))<\/li><\/ul>"},{"id":"928859-s-3-10","title":"Precautions","mono":"<ul><li>hypersensitivity has occurred and may lead to severe anaphylaxis; monitoring recommended (Wilate(R))<\/li><li>endogenous high levels of factor VIII; may be associated with thrombosis (Alphanate(R), Humate-P(R))<\/li><li>females; increased risk of thromboembolic events (Alphanate(R), Humate-P(R))<\/li><li>human plasma product; may contain infectious agents including viruses and theoretical risk of Creutzfeldt-Jakob disease agent<\/li><li>neutralizing antibodies to von Willebrand factor may occur (Wilate(R))<\/li><li>pre-existing thrombosis risk factors; increased risk of thromboembolic events<\/li><li>pregnant women and immunocompromised patients; in the event of transmission of infection, parvovirus B19 transmission presents a more serious risk (Alphanate(R), Humate-P(R))<\/li><li>sustained excessive levels of von Willebrand factor and factor VIII; increased risk of thrombotic events; monitoring recommended (Wilate(R))<\/li><li>report suspected transmission of infection from Humate-P(R) to CSL Behring 1-800-504-5434<\/li><li>report suspected transmission of infection from Alphanate(R) to Grifols Biologicals at 1-888-675-2762<\/li><li>report suspected adverse reactions from Wilate(R) to Octapharma USA Inc. at 1-866-766-4860 or the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"928859-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Antihemophilic Factor: C (FDA)<\/li><li>Von Willebrand Factor Complex (Human): Unknown<\/li><\/ul>"},{"id":"928859-s-3-12","title":"Breast Feeding","mono":"<ul><li>Antihemophilic Factor: WHO: Compatible with breastfeeding.<\/li><li>Antihemophilic Factor: Micromedex: Infant risk is minimal.<\/li><li>Von Willebrand Factor Complex (Human): Unknown<\/li><\/ul>"}]},"5":{"id":"928859-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema of face<\/li><li><b>Dermatologic:<\/b>Pruritus, Rash, Urticaria<\/li><li><b>Gastrointestinal:<\/b>Nausea<\/li><li><b>Neurologic:<\/b>Dizziness, Headache, Paresthesia<\/li><li><b>Respiratory:<\/b>Pharyngitis<\/li><li><b>Other:<\/b>Factor VIII inhibitor disorder, Pain, Shivering<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Fibrinogen in blood above reference range (rare), Hemolytic anemia (rare), Thromboembolic disorder<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Respiratory:<\/b>Pulmonary thromboembolism<\/li><li><b>Other:<\/b>Viral disease, Transmission<\/li><\/ul>"},"6":{"id":"928859-s-6","title":"Drug Name Info","sub":{"0":{"id":"928859-s-6-17","title":"US Trade Names","mono":"<ul><li>Humate-P<\/li><li>Alphanate<\/li><li>Wilate<\/li><\/ul>"},"2":{"id":"928859-s-6-19","title":"Class","mono":"Antihemophilic Agent<br\/>"},"3":{"id":"928859-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928859-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928859-s-7","title":"Mechanism Of Action","mono":"Antihemophilic Factor VIII\/ von Willebrand Factor Complex (Human) is a lyophilized concentrate of Factor VIII and von Willebrand Factor, which facilitates the activation of Factor X ultimately causing the formation of thrombin and fibrin promoting platelet aggregation and adhesion to damaged vascular endothelium.<br\/>"},"8":{"id":"928859-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"928859-s-8-24","title":"Distribution","mono":"<ul><li>von Willebrand Factor:Ristocetin Cofactor, Vd: 53 to 69.7 mL\/kg<\/li><li>Factor VIII, Vd: 72.4 mL\/kg<\/li><\/ul>"},"4":{"id":"928859-s-8-27","title":"Elimination Half Life","mono":"<ul><li>von Willebrand Factor:Ristocetin Cofactor, 6.91 to 15.8 hr<\/li><li>Factor VIII, 12.2 to 19.6 hr<\/li><\/ul>"}}},"9":{"id":"928859-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IV administration only<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>warm product to room temperature before reconstitution<\/li><li>gently swirl vial to dissolve the lyophilized concentrate, do not shake vial<\/li><li>administer within 3 hours after reconstitution<\/li><li>administer Wilate(R) immediately after reconstitution<\/li><li>administer Alphanate(R) slowly, up to a maximum rate of 10 mL\/minute.<\/li><li>administer Humate-P(R) slowly up to a maximum of 4 mL\/minute<\/li><li>administer Wilate(R) slowly at a rate of 2 to 4 mL\/minute<\/li><\/ul><\/li><\/ul>"},"10":{"id":"928859-s-10","title":"Monitoring","mono":"<ul><li>CBC; to monitor for adequate therapeutic response<\/li><li>(Alphanate(R)) for treatment of hemophilia A: plasma Factor VIII levels; periodically to evaluate individual patient response to the dosing regimen<\/li><li>(Humate-P(R)) for treatment of hemophilia A: plasma Factor VIII activity; frequently in order to individually adjust dose<\/li><li>(Humate-P(R)) for prevention of excessive bleeding during and after surgery in patients with von Willebrand disease: Factor VIII levels; using standard coagulation tests, especially in cases of surgery; von Willebrand Factor:Ristocetin Cofactor (VWF:RCo) levels<\/li><li>(Humate-P(R)) for prevention of excessive bleeding during and after surgery in patients with von Willebrand disease: trough levels of von Willebrand Factor:Ristocetin Cofactor (VWF:RCo) and plasma Factor VIII activity (FVIII:C) levels; at least once a day to adjust the dosage as needed to avoid excessive accumulation of coagulation factors<\/li><li>(Humate-P(R)) for treatment of spontaneous and trauma-induced bleeding in patients with von Willebrand disease: Factor VIII levels; using standard coagulation tests<\/li><li>(Humate-P(R)) for treatment of spontaneous and trauma-induced bleeding in patients with von Willebrand disease: trough levels of von Willebrand Factor:Ristocetin Cofactor (VWF:RCo) and plasma Factor VIII activity (FVIII:C) levels; at least once a day to adjust the dosage as needed to avoid excessive accumulation of coagulation factors<\/li><li>(Humate-P(R)) for treatment of spontaneous and trauma-induced bleeding in patients with von Willebrand disease: incremental in vivo recovery (IVR) measurements, and baseline plasma von Willebrand Factor:Ristocetin Cofactor (VWF:RCo) and plasma Factor VIII activity (FVIII:C) assessment; prior to surgery<\/li><li>(Wilate(R)): appropriate laboratory tests on the patient's plasma; at suitable intervals whenever possible to assure that adequate von Willebrand Factor:Ristocetin Cofactor (VWF:RCo) and plasma Factor VIII activity (FVIII:C) levels have been achieved and are maintained<\/li><li>reduction in bleeding episodes is indicative of efficacy<\/li><li>plasma levels of von Willebrand Factor:Ristocetin Cofactor (VWF:RCo) and coagulation factor VIII (FVIII) complex activities; to avoid sustained excessive VWF and FVIII activity levels<\/li><li>presence of von Willebrand factor and coagulation factor VIII complex inhibitor development<\/li><li>signs of intravascular hemolysis and decreasing hematocrit; in patients with type A, B, or AB blood who require large and\/or frequent doses<\/li><li>(Wilate(R)): pulse rate; before and during injection<\/li><li>(Wilate(R)): signs and symptoms of hypersensitivity or allergic reactions that may progress to severe anaphylaxis, including shock<\/li><\/ul>"},"11":{"id":"928859-s-11","title":"How Supplied","mono":"<ul><li><b>Alphanate<\/b><br\/>Intravenous Powder for Solution: (Antihemophilic Factor VIII Human - Von Willebrand Factor Complex (Human)) 1 IU-1 IU<br\/><\/li><li><b>Humate-P<\/b><br\/>Intravenous Powder for Solution: (Antihemophilic Factor VIII Human - Von Willebrand Factor Complex (Human)) 1 IU-1 IU<br\/><\/li><li><b>Wilate<\/b><br\/>Intravenous Powder for Solution: (Antihemophilic Factor VIII Human - Von Willebrand Factor Complex (Human)) 1 IU-1 IU<br\/><\/li><\/ul>"}}}